Client Service Receipt Inventory as a standardised tool for measurement of socio-economic costs in the rare genetic disease population (CSRI-Ra)

Author:

Chung Claudia C. Y.,Fung Jasmine L. F.,Lui Adrian C. Y.,Chan Marcus C. Y.,Ng Yvette N. C.,Wong Wilfred H. S.,Lee So Lun,Knapp Martin,Chung Brian H. Y.

Abstract

AbstractThe measurement of costs is fundamental in healthcare decision-making, but it is often challenging. In particular, standardised methods have not been developed in the rare genetic disease population. A reliable and valid tool is critical for research to be locally meaningful yet internationally comparable. Herein, we sought to develop, contextualise, translate, and validate the Client Service Receipt Inventory for the RAre disease population (CSRI-Ra) to be used in cost-of-illness studies and economic evaluations for healthcare planning. Through expert panel discussions and focus group meetings involving 17 rare disease patients, carers, and healthcare and social care professionals from Hong Kong, we have developed the CSRI-Ra. Rounds of forward and backward translations were performed by bilingual researchers, and face validity and semantic equivalence were achieved through interviews and telephone communications with focus group participants and an additional of 13 healthcare professional and university students. Intra-class correlation coefficient (ICC) was used to assess criterion validity between CSRI-Ra and electronic patient record in a sample of 94 rare disease patients and carers, with overall ICC being 0.69 (95% CI 0.56–0.78), indicating moderate to good agreement. Following rounds of revision in the development, contextualisation, translation, and validation stages, the CSRI-Ra is ready for use in empirical research. The CSRI-Ra provides a sufficiently standardised yet adaptable method for collecting socio-economic data related to rare genetic diseases. This is important for near-term and long-term monitoring of the resource consequences of rare diseases, and it provides a tool for use in economic evaluations in the future, thereby helping to inform planning for efficient and effective healthcare. Adaptation of the CSRI-Ra to other populations would facilitate international research.

Funder

Health and Medical Research Fund

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Reference30 articles.

1. World Health Organization. Priority Diseases and Reasons for Inclusion. https://www.who.int/medicines/areas/priority_medicines/Ch6_19Rare.pdf (2013).

2. Šimerka, P. Council Recommendation of 8 June 2009 on an Action in the Field of Rare Diseases (2009/C 151/02). (Official Journal of the European Union, 2009).

3. Baldovino, S., Moliner, A. M., Taruscio, D., Daina, E. & Roccatello, D. Rare diseases in Europe: From a wide to a local perspective. Isr. Med. Assoc. J. 18(6), 359–363 (2016).

4. Austin, C. P. et al. Future of rare diseases research 2017–2027: An IRDiRC perspective. Clin. Transl. Sci. 11(1), 21–27 (2018).

5. Thorn, J. C. et al. Resource-use measurement based on patient recall: Issues and challenges for economic evaluation. Appl. Health Econ. Health Policy. 11(3), 155–161 (2013).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3